Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06999577 · ClinicalTrials.gov registry record · Phase 4
The Mechanism Versus PPI Trial
A Phase 4 study of Cough and Dysphonia, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT06999577: Recruiting Phase 4 study of Cough and Dysphonia, sponsored by University of California, San Diego.
NCT06999577 is a Phase 4 study of Cough and Dysphonia that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 160 participants, below the 209-participant average among 12 other Cough trials with a reported enrollment target (23% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06999577, a Phase 4 study of Cough and Dysphonia, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if a mechanism guided strategy that utilizes a multidisciplinary approach to treat adults patients (age 18-89) with chronic throat symptoms who are undergoing clinical evaluation for laryngopharyngeal reflux (LPR) is more effective than the usual care strategy with proton pump inhibitor (PPI) therapy used in gastroenterology for these patients. The main question it aims to answer is: Will a greater proportion of the mechanism guided strategy participants achieve symptom response in comparison to the usual care strategy participants? If there is a comparison group: Researchers will compare the mechanism guided strategy to usual care strategy to see if treatment response differs between the groups. Participants will be be asked to do the following: * participate in an 8-week blinded study phase where they will be randomized to either 1) Mechanism Guided Strategy or 2) Usual Care Strategy * take an oral capsule daily (omeprazole 40mg or placebo) * come to 3 in-person visits at UC San Diego Health for an intervention visit with a study provider * consider incorporating recommended lifestyle modifications * complete weekly surveys
Primary Outcome
Proportion of subjects with symptom response measured by the reflux symptom index (RSI) score.
Conditions Studied
Interventions
- DRUG Omeprazole 40 MG
- BEHAVIORAL Laryngeal Recalibration Therapy
- BEHAVIORAL GERD Lifestyle Recommendations
Study Locations (1)
California
- University of California San Diego - San Deigo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-06-04 |
| Est. Completion | 2029-07-01 |
| Phase | Phase 4 |
What NCT06999577 shows while recruiting
NCT06999577 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 209-participant average among 12 other Cough trials with a reported enrollment target (23% lower).
The record links to 5 conditions, with Cough appearing as the primary indexed condition, and to 3 interventions - of which Omeprazole 40 MG is the first listed.
NCT06999577 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06999577 about?
NCT06999577 is a clinical study titled "The Mechanism Versus PPI Trial". The goal of this clinical trial is to learn if a mechanism guided strategy that utilizes a multidisciplinary approach to treat adults patients (age 18-89) with chronic throat symptoms who are undergoing clinical evaluation for laryngopharyngeal reflux (LPR) is more effective than the usual care stra...
What is the current status of trial NCT06999577?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 160 participants. The study started on 2025-06-04. Estimated completion is 2029-07-01.
What conditions does trial NCT06999577 study?
This clinical trial studies the following conditions: Cough, Dysphonia, Laryngopharyngeal Reflux, Reflux, Throat Clearing.
What interventions are being tested in trial NCT06999577?
The interventions under investigation include: Omeprazole 40 MG (DRUG), Laryngeal Recalibration Therapy (BEHAVIORAL), GERD Lifestyle Recommendations (BEHAVIORAL).
Who is sponsoring clinical trial NCT06999577?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06999577 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cough
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06999577's enrollment target sits among peer trials
160 4th of 12 higher than 9 of 12 other Cough trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cough trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin
COMPLETED · Phase 4
-
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
RECRUITING · Phase 3
-
Office-Based Superior Laryngeal Nerve Block for Treatment of Neurogenic Cough
RECRUITING
-
Stimulation of the Larynx to Treat Unexplained Chronic Cough
RECRUITING · NA
-
Work of Breathing Assessment in Triage Scale
ACTIVE NOT RECRUITING
-
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI